We have analyzed the ability of an adenoviral vector encoding the exon 1b region of the p14 ARF tumor suppressor ( ARF ) to suppress the growth and viability of an array of tumor cell lines of various origins and varying p53 and Rb status, in order to establish the clinical potential of ARF. An important activity of ARF is regulation of p53 stability and function through binding to the mdm2 protein.
T he ARF tumor suppressor (p14 ARF in humans, p19 ARF in mice) is encoded within the INK4a locus on chromosome 9p21 and acts upstream of p53 to regulate its stability and function. 1, 2 By interacting with mdm2 and blocking mdm2 -mediated degradation of p53, 1 -5 ARF enhances sequence -specific transcriptional transactivation by p53 2, 4 and restores mdm2-abrogated, p53 -mediated cell cycle arrest. 1 The exon 1b-encoded sequence of ARF is the most conserved region between mice and humans, particularly in the first 25 amino acid residues, and is sufficient to inhibit mdm2 activity, stabilize p53, and induce cell cycle arrest. 6 ARF exerts its tumor suppressor activity primarily by enhancing p53 stability and function, but may promote growth suppression through the Rb pathway as well, 7, 8 possibly through an effect on mdm2, which has been shown to bind to Rb and inhibit its function. 7 The importance of ARF for tumor suppression in vivo is evident from studies of mice generated through targeted disruption of exon 1b, and therefore lacking ARF function. Such mice are highly cancer-prone and show a phenotype similar to that of mice lacking p53. 4 In human cancer, ARF gene deletion has now emerged as the second most frequent event in cancer ( second to p53 gene alteration ), occurring in some 40% of cancers overall. 9 -13 ARF and p53 abnormalities have been observed to occur in a reciprocal manner in certain cancers, as would be expected based on the model in which ARF and p53 play roles in the same pathway. 11 -13 Although the high frequency of ARF gene deletion in most human cancers and its involvement in two central pathways of tumor suppression would make ARF a prime candidate for therapeutic application for cancer, the possibility that its tumor suppressor activity requires that either the p53 or Rb pathway be intact is a potential limitation to its application, as these pathways are frequently lost together in cancer. To further understand the interdependence of ARF and p53 in human tumor lines of known endogenous ARF and p53 status, we have examined the response of these cell lines to adenoviral vectors encoding p53 or the exon 1b portion of human ARF (Ad1b). We find that whereas endogenous p53 status is a strong predictor of cellular response to Ad1b, consistent with the above model, Ad1b is able to suppress the growth and viability of tumors cells lacking endogenous expression of wild -type p53, and lacking a functional RB pathway as well, inducing partial or complete cell cycle arrest as well as cell death in these cells. The results support a p53-dependent mechanism for ARF, but point to a mechanism for ARF that is independent of p53 as well.
Materials and methods

Cell lines and growth conditions
All cell lines except N202 were obtained from the American Type Culture Collection (ATCC, Rockville, MD ). An estrogen receptor -negative clone of MCF7 cells derived from the ATCC MCF7 cell line 14 was used in these studies. Murine N202 cells were kindly provided by Dr Joseph Lustgarten (Sidney Kimmel Cancer Center, San Diego, CA ) and were originally derived from FVB -neuN mice ( N202 ) bearing the rat neu protooncogene driven by the mouse mammary tumor virus ( MMTV ) promoter /enhancer. 15 Such mice are predisposed to spontaneous mammary carcinomas that overexpress the rat p185/neu protein. N202 cells express wild -type p53 and express endogenous ARF ( Y Huang, unpublished data ). To facilitate in vivo detection of N202 cells, they were modified with an expression vector encoding an H2B -Green Fluorescent Protein (GFP ) fusion protein (vector kindly provided by Dr Geoffrey Wahl, Salk Institute ). All cell lines were maintained at 378C in 10% CO 2 in Dulbecco's modified Eagle's medium ( DMEM ) supplemented with nonessential amino acids, pyruvate, and L -glutamine. Fetal bovine serum (heatinactivated at 568C for 30 minutes ) was added to 10%. All media, additives, and serum were obtained from Irvine Scientific ( Santa Ana, CA ).
Reverse transcriptase polymerase chain reaction ( RT -PCR )
The expression of ARF in various tumor cell lines was determined by RT-PCR using primers designed to amplify a 300 -bp fragment of the message encoded by ARF exon 1b ( ARF forward: 5 0 -GATATACTCGAGCTGCTCACCTC -3 0 ; ARF exon 1b reverse: 5 0 -GTATAGGATCCCTGGTCTTC-TAGG -3 0 ). Total cellular RNA was prepared from about 5Â10 5 cells using the RNeasy 2 kit from Qiagen (Valencia, CA ) and following the manufacturer's procedure. Five micrograms of RNA was reverse -transcribed into cDNA in a 22 -L reaction containing 0.5 mM each of deoxyribonucleotide triphosphate ( dNTP ), 50 g /mL oligo deoxythymidine ( oligo -dT ), 40 U of rRNAsin, 200 U of Moloney Murine Leukemia Virus reverse transcriptase and reverse transcriptase buffer. Control reactions that lacked reverse transcriptase were included, in order to control for the presence of genomic sequences. In all cases, control reactions produced no signal upon PCR amplification. This cDNA was then used as a template for PCR. PCR reactions were performed in 25 L using 3 L of cDNA, 25 pmol each of forward and reverse primers, 250 M each of dNTP ( Pharmacia, Piscataway, NJ ) 1.25 U of Taq polymerase, Â1 buffer, and solution Q (Qiagen ), followed by electrophoresis on a 1% agarose gel containing 0.5 g /mL ethidium bromide. The amplification program was as follows: 1 cycle (948C for 1 minute, 30 seconds ), 29 cycles (948C for 1 minute, 578C for 1 minute, 708C for 2 minutes, 30 seconds ), and 1 cycle (948C for 1 minute, 578C for 1 minute, 708C for 7 minutes ). dNTPs for PCR and cDNA preparation were purchased from Pharmacia. Oligo -dT, reverse transcriptase and buffer, and rRNAsin were purchased form Promega ( Madison, WI ). All other PCR reaction components were purchased from Qiagen.
Western analyses
Cell lysates (50 g) were electrophoresed on a 15% acrylamide gel and blotted onto PVDF membranes (Osmonics, Minnetonka, MN ). Membranes were then treated with primary antibody: p53 (1:500 ), ARF ( 1:500 ), mdm2 ( 1:500 ), bax (1:200 ), and bcl 2 (1:100 ). Mouse monoclonal anti-p53 ( Ab -6 ) was purchased from Oncogene Research Products ( Cambridge, MA ). Rabbit polyclonal anti -p14 ARF (fulllength protein ) was purchased from Zymed Laboratories ( South San Francisco, CA ). Mouse monoclonal anti -mdm2 ( human ) SMP14, rabbit polyclonal anti -bax, mouse monoclonal anti -bcl 2 , mouse monoclonal antiactin, and horseradish peroxidase -conjugated antirabbit and antimouse secondary antibodies were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA ). Treatments were carried out according to the protocol recommended by the manufacturer. Antibody reactive bands were revealed using the ECL + Plus Western blotting detection system ( Amersham Biosciences, Piscataway, NJ ). For quantitation of bands, we used Kodak digital camera and analysis software ( Kodak, Rochester, NY ). To control for equivalent loading, blots were stripped and reprobed with antiactin antibody.
Growth and viability assays
Cells at 60 -70% confluency in 24-well plates were treated with adenoviral vectors in a medium containing 2% fetal bovine serum at varying multiplicities of infection and times and then replated in triplicate in 96 -well plates at 3000 cells / well (for 72-hour assays ) or 1000 cells / well ( for 6-day assays ) in complete medium. Under these conditions, control ( untreated ) wells remained subconfluent and in exponential phase growth for the duration of the assay. After 72 hours (in some experiments 6 days ), 20 L of a solution containing 333 g /mL MTS ( 3 -(4,5 0 -dimethylthiazol -2 -yl )-5 -(3 -carboxymethoxylphenyl-2-(4-sulfophenyl)-2H-tetrazolium inner salt )) ( Promega ) and 25 g /mL PMS (phenazine methosulfate ) ( Sigma, St. Louis, MO ) was added to each well of the 96 -well plate. The plate was incubated at 378C for approximately 1 hour in a humidified 10% CO 2 atmosphere, and OD at 490 nm, proportional to the number of viable cells, was determined using an ELISA reader. Viability was expressed as a percentage of control, mockinfected cell viability.
Animal chamber model
Tumor cell spheroids of N202 cells were prepared by placing 150 L /well of N202 cells ( 10 5 cells) in DMEM containing 10% fetal bovine serum in 96 -well roundbottom plates coated with 1% agarose in serum -free DMEM for a liquid overlay. Plates were incubated at 378C in 10% CO 2 for 48 hours. Compacted 100,000-cell spheroids were removed from 96 -well plates, washed in serum -free medium, and implanted into the dorsal skinfold chamber of nude mice as previously described. 14, 16, 17 Intravital microscopy was performed using a Mikron fluorescence microscope (Mikron Instruments, San Diego, CA ) equipped with an epi -illuminator. A silicon -intensified target camera ( SIT68; Dage -MTI, Michigan City, IN ) is
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Tumor suppression by p14 ARF exon 1b N Saadatmandi et al attached to the microscope. Visualization of tumor growth in the chamber was achieved using a GFP C 3902 filter cube ( Chroma, Battleboro, VT ). Cell viability was visualized by the intrinsic fluorescence of H2B -GFP, permitting evaluation of chromatin integrity under Â20 and Â63 objectives. Anaphase figures, nuclear karyohexis, and pykcotic nuclei were easily identified under high -power microscopy. Five days following implantation of cells, chambers were injected with 2Â10 8 pfu of Ad1b or AdLuc, and chambers were observed 24 hours later.
Trypan Blue exclusion assay
Duplicate wells of cells in 24-well plates were assayed 48 hours post vector treatment. Medium plus floating cells were removed (1 mL ) and the attached cells were detached from the plate with 100 L of 0.05% trypsin in phosphatebuffered saline ( PBS ), and combined with the medium plus floating cells. A total of 200 L of Trypan Blue stain ( 0.4% in PBS; Sigma ) was added to the cells and the percentage of blue -stained, nonviable cells was determined by cell counting. Averages and standard deviations were calculated.
Annexin V staining
Cells were plated in 24 -well plates, treated with vector, and stained with Annexin V 24 hours later using the Annexin V apoptosis detection kit ( Santa Cruz, Biotechnology, Santa Cruz, CA ) according to the manufacturer's instructions. Briefly, the medium was removed and cells were washed once in PBS and once in assay buffer. Cells were then stained by adding 300 L of assay buffer per well, 3 L of Annexin V, and 30 L of propidium iodide. Plates were observed with a fluorescence microscope and photographed immediately.
Cell cycle analysis
Cells in 6 -or 10 -cm culture plates were treated with vector and adherent cells were harvested 48 hours later. Cells were fixed and stained with propidium iodide as previously described. 18 Cell cycle analysis was carried out using a FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ ). DNA histograms were analyzed with the ModFit program using doublet discrimination. Each analysis was performed in duplicate or triplicate.
Adenoviral vectors
A replication -defective adenoviral vector was constructed in which the viral E1A and E1B genes were replaced with the ARF exon 1b coding sequence, together with the CMV promoter and SV40 polyadenylation signal, using the pE1sp1A and PJM17 plasmids available from Microbix ( Toronto, Ontario, Canada ). The sequences encoding ARF exon 1b were obtained by PCR amplification from normal human skin fibroblast cDNA, using primers described above ( see RT-PCR ). Viral packaging was accomplished by cotransfection of human kidney 293 cells ( low passage; Microbix ) with these two plasmids, followed by overlaying the cells with complete medium containing 1% agarose and incubating at 378C in 10% CO 2 until plaques appeared ( about 3 weeks). The virus was isolated from these plaques, expanded, and purified on cesium chloride gradients using published procedures 19 and characterized for the ability to induce expression of ARF exon 1b in the ARF -negative cell line MCF7, as determined by RT-PCR and Western analysis. Viral titers in viral particles (vp ) per milliliters were determined by measuring the OD 260 nm and calculating concentration based on the relationship: 1 OD( 260 )= 10 12 vp/mL. Viral titers in plaque -forming units per milliliter ( pfu / mL ) were determined by an endpoint dilution assay on 293 cells in 96-well plates as described for the TCID 50 assay in the Quantum Biotechnologies AdEasy 2 applications manual (Quantum Biotechnologies, Carlsbad, CA ), and found to be 10 11 pfu /mL. The vp -to -pfu ratio was 70. Replication -competent virus was not detectable in 10 10 vp assayed on human fibroblasts.
Replication -defective adenoviral vectors encoding human wild -type p53 ( RPR / INGN201, Ad5CMV-p53), firefly luciferase, and bacterial b -galactosidase were provided by Introgen Therapeutics (Houston, TX ). 20, 21 These are referred to here as Adp53, AdLuc, and Adbgal, respectively, and have been used previously in our studies. 22 The p53 and b-galactosidase genes are expressed from the Cytomegalovirus promoter. The luciferase gene is expressed from the Rous Sarcoma Virus promoter. All vectors are E1A -and E1B -deleted. Viral titers were as follows: Adp53: 3.6Â10 10 pfu /mL; AdLuc: 2Â10 11 pfu /mL; and Ad1b: 10 11 pfu/mL. The vp -to -pfu ratios were about 50 -80 for all three vectors.
X -gal staining
To assess the efficiency of adenoviral infection in each cell line, cells were treated with varying doses of Adbgal for 3 hours, and 48 hours following vector treatment, cells were fixed in 3.7% formaldehyde in PBS and stained with the b -galactosidase substrate X -gal (5 -bromo -4 -chloro -3 -indoyl -b-D -galactopyranoside ), which generates a blue -colored product in cells expressing the transduced b -galactosidase gene, as previously described. 18 
Results
Frequent reciprocity of ARF and p53 abnormalities in human tumor cell lines
We investigated by RT-PCR, the ARF status in a panel of 17 human tumor cell lines of known p53 status ( Table 1 ) . p53 abnormalities occurred in 14 of 17 cell lines examined, with a reciprocal relationship between ARF and p53 abnormalities occurring in 13 of 17 cell lines. Three cell lines, T98G glioblastoma, U373 glioblastoma, and SKOV3 ovarian carcinoma, had abnormalities in both p53 and ARF. LnCAP prostate cancer cells expressed ARF, which we confirmed by sequence analysis to correspond to the published wild -type sequence 23 ( data not shown ) and to retain wild -type p53 ( confirmed by sequence analysis; data not shown). As shown below, LnCAP cells do not appear to overexpress mdm2 protein, the other key modulator of p53 stability and function, and thus appear to have the p53 pathway intact.
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Broad tumor suppressor activity of Ad1 in human tumor cell lines
We constructed an E1A /E1B -deleted replication -defective adenovirus, denoted Ad1b, encoding the exon 1b portion of ARF -the region demonstrated to encode ARF tumor suppressor activity. 1 The tumor suppressor activity of Ad1b was verified using the MCF7 cell line that lacks endogenous ARF ( Fig 1A, lane a) and expresses endogenous wild -type p53 ( see Table 1 ). We observed that MCF7 cells treated with Ad1b underwent a dose -dependent increase in immunoreactive protein corresponding to ARF exon 1b (Fig 1A, lanes  b and c ) that correlated inversely with the viability of Ad1b-treated cultures (Fig 1B ) . Viability was measured by the MTS assay ( described in Materials and methods ) 72 hours following the start of treatment. The term viability is used throughout this study to mean the overall metabolic activity of the cell population as reflected by the bioconversion of a tetrazolium salt, MTS, to a colored product, and is proportional to the cell number. Suppression of viability refers to the percent decrease in overall metabolic activity of the vector-treated cell population relative to an untreated population. Equivalent loading on Western blots was verified by stripping the blots and reprobing with actin antibody (not shown ). No suppression of viability was observed in AdLuc -treated cultures ( Fig 1B ) , indicating that nonspecific vector-associated toxicity was undetectable.
As shown in Figure 2 , A and B, respectively, Ad1b also suppressed the in vitro viability and in vivo tumorigenicity of murine N202 cells, which express endogenous wild -type p53 as well as endogenous ARF (Table 1) . Treatment of N202 cells with 200 pfu /cell Ad1b for 3 hours resulted in 12± 2% Trypan Blue -stained cells, 48 hours after vector treatment, indicating that cell death occurred. Control vector -treated cells had no detectable staining. For visualization of in vivo effects, we used intravital video microscopy of tumor cell spheroids implanted in dorsal skinfold chambers in nude mice 14, 16, 17 followed by treatment with Ad1b or AdLuc (control ). To distinguish apoptosis from mitotic arrest, tumor cells had been modified ex vivo to 
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Tumor suppression by p14 ARF exon 1b N Saadatmandi et al constitutively express a Histone H2B -GFP fusion protein, a fluorescent marker protein that localizes to the chromatin and enables visualization of nuclear morphology. Murine N202 cells grow as a nonencapsulated tumor resembling a spontaneous tumor, unlike the majority of human tumor lines, including MCF7, in a murine environment ( P Borgstrom, unpublished data ), and they therefore allow us to assess the behavior of tumor cells in a growth environment more closely resembling a clinical situation. Five days following implantation, 2Â10 8 pfu of Ad1b or AdLuc (control ) was injected into the chamber, and the cellular response was observed 24 hours later. As shown in Figure 2B , treatment with Ad1b ( Right panel ), but not AdLuc ( Left panel ), led to a striking increase in cells with condensed and irregular nuclei characteristic of apoptotic cells. Therefore, Ad1b encodes an immunoreactive exon 1b protein with tumor suppressor function in both murine and human tumor cells and with activity both in vitro and in vivo.
To determine whether the tumor suppressor activity of Ad1b extended to human tumor cell lines of varying p53
and ARF status, we selected seven representative cell lines from those listed in Table 1 . The cell lines (Table 2) were chosen so as to represent each of the four possible states of p53 and ARF status: ( a) abnormal p53 only ( DU145, PC3 ); (b ) abnormal ARF only (MCF7, U87 ); (c ) abnormal p53 and ARF (T98G, SKOV3 ); and ( d) wild -type p53 and ARF (LnCAP). In addition, with the exception of LnCAP cells, all cell lines tested lacked expression of either Rb or p16, and therefore lacked a functional Rb pathway. 24 -30 The relative infectabilities of cell lines were variable, as determined 48 hours following treatment of cells with an adenoviral vector ( Adbgal ) expressing the bacterial bgalactosidase gene (see Materials and Methods ). Nevertheless, conditions that ensured a high percentage of transduced cells ( >80% ) in all cases based on X -gal staining could be found, and were as follows: 500 -1000 pfu /cell, overnight ( T98G, SKOV3); 500 pfu /cell, 3 hours (PC3 ); 200-500 
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These cell lines were then treated with varying doses of Ad1b, Adp53, or AdLuc ( control ), and cell viability was measured as for Figure 1 (see also Materials and Methods ) 72 hours following the start of treatment ( Fig 3 ) . Vector treatment also resulted in a reduction in [ 3 H ]thymidine incorporation into DNA that paralleled the results of the MTS assay ( data not shown). The results show that nonspecific vector-associated toxicity was minimal, as the AdLuc control vector was well tolerated by the lines under all conditions. Because all three viral preparations displayed similar vp -to -pfu ratios ( in the range of 50-80 ), nonspecific vector-associated toxicity was assumed to be similar for all three vectors.
We observed that suppression of viability ( defined above ) by Adp53 was independent of endogenous ARF and p53 status, as expected, and reached >95% for all cell lines tested. Suppression of 72-hour viability by Ad1b fell into one of three patterns that depended on endogenous p53 status: (a ) cell lines null for endogenous p53 expression ( SKOV3, PC -3 ) were not suppressed by Ad1b ( Fig 3A,  column 1 ; Table 2 ); and ( b) cell lines expressing endogenous mutant p53 (T98G, DU145 ) were less suppressed by Ad1b than they were by Adp53 at equivalent vector doses ( Fig 3A, column 1 ; Table 2 ). At the highest treatment dose of Ad1b, T98G and DU145 could be suppressed by about 50% and >95%, respectively, with data points being completely nonoverlapping with controls. Finally, (c) three cell lines expressing endogenous wild -type p53 (LnCAP, MCF7, U87 ) were suppressed by both Adp53 and Ad1b to similar extents at equivalent vector doses ( Fig 3A,  column 2 ; Table 2 ). In one cell line null for endogenous p53 (PC -3 ), growth and viability could be suppressed by about 25% by 6 days posttreatment ( Fig 3B ) . Thus, expression of endogenous wild -type p53 contributes to Ad1b -mediated suppression of tumor cell growth and viability, but is not strictly required. Furthermore, because T98G cells lack expression of the cyclin-dependent kinase inhibitor, p16, 27 and therefore have a defective Rb pathway, and DU145 cells express a nonfunctional Rb protein, 30 these results suggest an activity of ARF in human tumor cell lines that is independent of either the p53 or Rb pathway.
Induction of cell death and cell cycle arrest in Ad1b -treated cells in the absence of induction of p53 downstream targets
To determine the extent to which cell death or cell cycle arrest accounted for the Ad1b -mediated decrease in overall culture viability observed in Figure 3 , we performed quantitative Trypan Blue exclusion assays of total cell death, Annexin V staining assays of apoptotic cell death, and Flow Cytometric analyses of cell cycle changes 24 -48 hours after vector treatment of four representative cell lines (T98G, DU145, LnCAP, U87 ). Vector treatments were chosen based on Figure 3 to provide about 50 -70% suppression of the 72 -hour viability: ( a) 500 pfu /cell, overnight ( Ad1b, AdLuc ) and 500 pfu /cell, 3 hours (Adp53) for T98G and DU145; ( b ) 200 pfu /cell, 3 hours (all vectors) for LnCAP; and (c ) 500 pfu /cell, 3 hours (all vectors) for U87.
Trypan Blue staining, which measures cellular membrane breakdown characteristic of total cell death ( apoptotic + nonapoptotic), was carried out in duplicate 48 -hour postvector treatment. In control vector ( AdLuc ) -treated cells, viability was high and Trypan Blue -stained cells accounted for only a small percentage of the population: 1 ± 2% ( T98G ), 0 ± 0% (DU145 ), 1± 1% (LnCAP ), and 6 ± 2% (U87 ). In all four Adp53-treated cell lines ( irrespective of endogenous p53 status ), there was a marked increase in Trypan Blue staining relative to control vector -treated cells: 17± 5% ( T98G ), 37 ± 5% (DU145 ), 29± 3% ( LnCAP ), and 36 ± 1% ( U87 ), as expected. In three of four cell lines ( DU145, LnCAP, U87 ), Ad1b treatment also led to a marked increase in Trypan Blue staining: 13± 6% ( DU145 ), 29 ± 3% ( LnCAP ), and 36 ± 1% ( U87 ). One of these cell lines ( DU145 ) expressed endogenous mutant p53, indicating that Ad1b did not require endogenous wild -type p53 expression to induce cell death. 
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We used Annexin V -FITC binding to cells 24 hours after vector treatment to detect the early phases of apoptosis in live, intact cells prior to membrane permeabilization (Fig 4 ) . At this early stage, membrane -permeable cells ( detected by propidium iodide staining ) accounted for less than 1% of the cell population ( not shown ) and these were not scored for Annexin staining. Figure 4 shows typical Annexin staining patterns of T98G, DU145, LnCAP, and U87 cells following treatment with either Ad1b or Adp53. Annexin staining was not observed in control cultures or in cultures treated with AdLuc (not shown ). Annexin staining could be observed in all cell lines following treatment with Adp53, indicating that apoptosis was triggered by the treatment, and consistent with an elevated bax -to -bcl 2 ratio observed by Western analysis ( see below ). Following treatment with Ad1b, LnCAP cells and U87 cells that express endogenous wild -type p53 displayed Annexin staining, whereas T98G cells and DU145 cells that lack endogenous expression of wild -type p53 failed to display Annexin staining. Together with the results of the Trypan Blue Exclusion assay, these data suggest that apoptosis is not efficiently triggered by Ad1b unless cells express endogenous wild -type p53. However, even when apoptosis is not detected, a nonapoptotic form of cell death may contribute to the loss of viability observed after Ad1b treatment of some cell lines lacking endogenous expression of wild -type p53.
We used FACS analysis to examine cell cycle changes 48 hours following treatment with Ad1b or Adp53 ( Fig 5) . We found that Adp53 treatment induced an accumulation of cells with G1 DNA content in all four cell lines. Ad1b treatment induced an accumulation of cells with G1 DNA content ( LnCAP, T98G ), G2 DNA content (U87 ), or S /G2 DNA content ( DU145 ), and the arrest pattern could not be predicted from the endogenous p53 status of the cells. That is, U87 cells that expressed endogenous wild -type p53 were arrested in G1 by Adp53, and G2 by Ad1b. Taken together, the results of the Trypan Blue exclusion assay, the Annexin V staining assay, and the cell cycle analysis reveal differences in Ad1b -and Adp53-treated cells, which suggest that the pathways induced by the two vectors are, in part, different.
Western analysis of p53 target genes
We used Western blotting to examine the expression of the p53 target gene bax, known to be associated with apoptosis, in cell lysates prepared 72 hours after treatment with Ad1b or Adp53. Induction of mdm2, a p53 target involved in feedback regulation of p53 stability, and of p21, a p53 target involved in cell cycle arrest, was also examined. We also examined the expression of bcl 2 and calculated the bax -tobcl 2 ratio, a critical determinant of apoptosis. All cell lines except LnCAP were treated with 500 pfu / cell vector for 3 hours. LnCAP cells were treated with 200 pfu / cell vector for 1 hour.
As shown in Figure 6 (first and second rows), treatment of all cell lines with Adp53 resulted in an increase in p53 protein, and treatment of cells with Ad1b resulted in an increase in exon 1b protein, as expected. Endogenous levels 
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Tumor suppression by p14 ARF exon 1b N Saadatmandi et al of p53 and ARF were low to undetectable under our conditions. In all cell lines treated with Adp53, expression of p53 target genes mdm2 ( third row ), p21 ( fourth row ), and bax (fifth row ) was also induced relative to levels in AdLuctreated cells, and an increased bax-to -bcl 2 ratio indicative of induction of p53-mediated apoptosis was observed ( bottom row ). A second analysis of bax -to -bcl 2 ratios in independently prepared lysates gave similar results (not shown). The doublet band observed for mdm2 in T98G, DU145, and LnCAP cells may represent differentially phosphorylated forms or the products of multiple transcripts. 31 In cell lines expressing endogenous wild -type p53 ( LnCAP and U87 ), treatment with Ad1b led to increased levels of endogenous p53, consistent with the involvement of ARF in the p53/ mdm2 feedback loop, and resulted in increased expression of p53 downstream targets. Thus, expression of exon 1b triggered the p53 pathway in these cells.
In contrast, Ad1b treatment of T98G and DU145 cells that lack endogenous wild -type p53 expression did not result in increased expression of p53 or its downstream target genes. As shown in Figure 6 , levels of mdm2, p21, and bax following treatment of T98G or DU145 cells with Ad1b were similar to levels observed following treatment with control vector (AdLuc ). Bax -to -bcl 2 ratios in Ad1b -treated T98G and DU145 cells were also similar to ratios observed in control vector (AdLuc )-treated cells. Lysates from T98G cells treated overnight with 500 pfu /cell Ad1b (not shown ) gave results similar to those shown for 500 pfu /cell for 3 hours.
Discussion
This study examined the suppressive effects of a p14 ARF exon 1b adenovirus (Ad1b ) in human tumor cell lines of varying endogenous p53 and ARF status, so as to address the possible application of ARF -based therapies to the treatment of cancer. The high frequency with which the ARF gene is deleted in human cancer makes ARF a promising candidate for therapy. However, the possibility that efficient tumor suppression by ARF would require an intact p53 and /or Rb pathway raises a concern as to the generality of its application. We show that Ad1b is most effective in cell lines expressing endogenous wild -type p53. Ad1b has little to no activity in two cell lines that are null for endogenous p53 expression ( SKOV3, PC -3 ). However, Ad1b has tumor suppressor activity, as manifested by the induction of cell cycle arrest and/or cell death, in two human tumor cell lines expressing endogenous mutant p53 (T98G, DU145 ). Because these lines cells also lack a functional Rb pathway, the results point to an activity of ARF that is independent of p53 and Rb in these settings, through a mechanism that is unknown. Suppression of tumor cell growth and viability following treatment with Ad1b involves both the induction of cell death and cell cycle arrest. Induction of apoptosis by Ad1b, determined by Annexin V staining of vector-treated cells, is observed only in cells expressing endogenous wild -type p53.
Cell cycle analyses, Trypan Blue exclusion assays for cell death, and Annexin V staining assays of vector-treated cells pointed to both p53 -dependent and -independent activities of ARF. Thus, whereas apoptosis induction by Ad1b occurred only in cell lines expressing endogenous wildtype p53 (LnCAP, U87 ), induction of an apparently nonapoptotic form of cell death by Ad1b, revealed by Trypan Blue staining, could be observed in DU145 cells that express endogenous mutant p53. In addition, the cell cycle distribution observed in cells treated with Ad1b or Adp53 did not necessarily follow a pattern predicted from a model in which ARF acts entirely through the p53 pathway. Thus, Ad1b induced an accumulation of cells in G2 in U87 cells expressing endogenous wild -type p53, whereas Adp53 induced an accumulation of cells in G1 in these cells.
We used Western blot analysis of four representative cell lines ( T98G, DU145, LnCAP, U87 ) to examine the p53 downstream targets mdm2, p21, and bax, whose promoters are induced by p53. As expected, induction of these targets by Ad1b required that the cell express endogenous wild -type p53 (LnCAP, U87 ). Furthermore, Ad1b treatment induced an elevated bax-to -bcl 2 ratio characteristic of apoptosis only in cells expressing endogenous wild -type p53 ( LnCAP, U87 ), consistent with the Annexin V staining results. In contrast, Adp53 treatment induced these genes and resulted in an elevated bax-to -bcl 2 ratio in all four cell lines irrespective of endogenous p53 and ARF status. The results are consistent with wide range of studies showing that an important activity of ARF is induction of the p53 pathway. However, the fact that suppression of viability by Ad1b occurs in cells lacking endogenous p53, and in the absence of induction of the p53 pathway, points to additional pathways of suppression of ARF as well.
Numerous lines of evidence support a model in which p53 and ARF have interdependent roles. For example, p53 -mediated apoptosis in the developing lens of Rb À / À mice is attenuated in the absence of ARF expression. 2 And, whereas g -radiation -induced phosphorylation, stabilization, and accumulation of p53 occur in the absence of ARF, 4 the duration of that response is shortened in the absence of ARF expression. 32 Conversely, in some settings, ARF function depends on p53: ARF does not induce growth arrest of early passage mouse embryo fibroblasts (MEFs) nullizygous for Figure 6 Western blot analysis of p53, exon 1b, mdm2, bax, and bcl 2 expression in T98G, DU145, LnCAP, and U87 cells following treatment with AdLuc ( control ), Ad1b, or Adp53, as described in the text. The expression of bax and bcl 2 was quantitated using a Kodak camera and analysis software and the ratios of bax to bcl 2 following treatment with each vector are shown in the last row, after normalizing the ratios to that of AdLuc -treated cells. Each lane represents 50 g of protein. Equivalent loading was verified by stripping membranes and reprobing with actin antibody ( not shown ).
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Tumor suppression by p14 ARF exon 1b N Saadatmandi et al p53. 2 -4,33 Suppression of transformation of rat fibroblasts by ARF also requires expression of wild -type p53. 2 Nevertheless, it is becoming increasingly clear that the functions of ARF and p53 are not entirely interdependent. A reciprocal relationship between ARF loss and p53 mutation has not been observed in all cancers, for example, 34, 35 suggesting that inactivation of ARF per se may constitute an independent survival advantage for the cancer cell. Moreover, triple knockout mice nullizygous for p53, mdm2, and ARF display a broader spectrum of tumors that develop more rapidly compared to double knockout mice lacking only p53 and mdm2, or single knockout mice lacking only p53, indicating that ARF expression in single or double knockout mice reduces tumor formation. In one study, MEFs from mice nullizygous for p53, mdm2, and ARF were observed to be growth -suppressed by ectopic reexpression of ARF, indicating that ARF is able to suppress cell growth independently of p53 in some cases. 36 Another study reported that immortalized MEFs from p53 nullizygous mice could be growth -suppressed by ectopic expression of ARF, whereas inactivation of both the p53 and Rb pathways effectively abrogated growth suppression by ARF. 8 These results reveal a more complex pattern of suppression by ARF and p53 -one that might not be predicted simply on the basis of endogenous p53 and ARF status. In the present study, Ad1b -mediated suppression of T98G and DU145 cannot be explained by an absence of mdm2 expression, as mdm2 was readily detected in these cells, or by an Rb pathway-mediated effect, as both cell lines had defects in this pathway. ARF has now been found to interact with several proteins in addition to mdm2, including E2F -1, 37 topoisomerase, 38 and mdmx, 39 and these or other proteins may play roles in ARF activity in certain human tumor cells. One possibility, though speculative, is that an interaction of ARF with the DNA replicative machinery could disrupt mitosis and lead to cell death through nonapoptotic and p53-independent mitotic catastrophe.
The tumor suppressor activity of an adenoviral vector encoding full -length ARF has been evaluated in cell lines derived from mesothelioma, a cancer characterized by frequent deletions of the INK4A locus and rare mutations of p53. In that study, mesothelioma cell lines lacking expression of ARF and expressing wild -type p53 were markedly growth -suppressed and underwent apoptosis following treatment with a ARF adenovirus, an observation that supports the therapeutic application of ARF gene therapy for that disease. 40 Our results with an adenoviral vector encoding only the exon 1b portion of ARF are consistent with this study, and suggest in addition that the therapeutic application of ARF may extend to a broader range of tumors lacking wild -type p53, or lacking both wild -type p53 and Rb pathways.
Therapeutic applications of the p53 tumor suppressor are already in an advanced stage of development, with numerous clinical trials ongoing or completed that attest to the safety and efficacy of adenovirus -mediated p53 gene transfer in cancer patients. 41 -45 Because ARF -based therapies may be highly effective in certain cancers and involve, in part, pathways that are independent of p53, an extension of these clinical approaches to include ARF gene transfer seems feasible, and potentially promising for many cancers. A better understanding of the tumor suppressor activity of ARF, particularly the activity that is independent of p53, may also reveal new opportunities for therapeutic intervention.
